About GLPION

We are a GLP-1 peptide API platform with four Type II DMFs on file with the U.S. FDA and a portfolio of 20+ peptide APIs — operated by 深贸国际 (Shenmao International).

Who We Are

A GLP-1-focused peptide API manufacturer supplying licensed pharmaceutical companies in patent-expired markets and qualified research institutions worldwide.

Regulatory readiness: four Type II DMFs on file with the U.S. FDA — semaglutide, liraglutide, tirzepatide and retatrutide.
FDA-inspected facility with Green List status; FDA NDC labeler codes 83589 & 83821.
Product platform: 20+ peptide APIs across four lines — GLP-1 analogues, growth-hormone secretagogues, research peptides and biomedicinal enzymes.
Quality system: cGMP manufacturing, batch-level COA, stability and impurity control, full export documentation.
Compliance-first strategy: supply aligned with each market's patent status — commercial supply where patents have expired, research use (RUO) elsewhere.

Platform at a Glance

4 FDA DMFs

Semaglutide (039209) · Liraglutide (033912) · Tirzepatide (040378) · Retatrutide (042689)

20+ Peptide APIs

GLP-1 analogues, growth-hormone secretagogues, research peptides and biomedicinal enzymes.

FDA Inspected · Green List

U.S. FDA on-site inspection completed; Green List status; NDC labeler codes 83589 & 83821.

Markets & Compliance

We align supply with patent and regulatory status in each market:

Brazil — semaglutide compound patent expired March 2026; supply to ANVISA-registered manufacturers for commercial production.
China — compound patent expired March 2026.
Australia — generic-entry window ~April 2027; partnership supply under discussion, research use now.
United States — compound patents in force until December 2031; research use only, plus partnerships with ANDA holders.